Evidence map›Paper›PMID 35693786›Full record

ArticleFrontiers in immunology2022

A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.

Zhenyu Zhao, Wei Yin, Xiong Peng, Qidong Cai, Boxue He, Shuai Shi, Weilin Peng, Guangxu Tu, Yunping Li, Dateng Li and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Zhenyu ZhaoDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Wei YinDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Xiong PengDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Qidong CaiDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Boxue HeDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Shuai ShiDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Weilin PengDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Guangxu TuDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Yunping LiDepartment of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha, China.
Dateng LiWhite Plains, NY, United States.
Yongguang TaoDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Muyun PengDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Xiang WangDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Fenglei YuDepartment of Thoracic Surgery, The Second Xiangya Hospital of Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CNWhite Plains Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Screening for early-stage lung cancer with low-dose computed tomography is recommended for high-risk populations; consequently, the incidence of pure ground-glass opacity (pGGO) is increasing. Ground-glass opacity (GGO) is considered the appearance of early lung cancer, and there remains an unmet clinical need to understand the pathology of small GGO (<1 cm in diameter). The objective of this study was to use the transcriptome profiling of pGGO specimens <1 cm in diameter to construct a pGGO-related gene risk signature to predict the prognosis of early-stage lung adenocarcinoma (LUAD) and explore the immune microenvironment of GGO. pGGO-related differentially expressed genes (DEGs) were screened to identify prognostic marker genes with two machine learning algorithms. A 15-gene risk signature was constructed from the DEGs that were shared between the algorithms. Risk scores were calculated using the regression coefficients for the pGGO-related DEGs. Patients with Stage I/II LUAD or Stage IA LUAD and high-risk scores had a worse prognosis than patients with low-risk scores. The prognosis of high-risk patients with Stage IA LUAD was almost identical to that of patients with Stage II LUAD, suggesting that treatment strategies for patients with Stage II LUAD may be beneficial in high-risk patients with Stage IA LUAD. pGGO-related DEGs were mainly enriched in immune-related pathways. Patients with high-risk scores and high tumor mutation burden had a worse prognosis and may benefit from immunotherapy. A nomogram was constructed to facilitate the clinical application of the 15-gene risk signature. Receiver operating characteristic curves and decision curve analysis validated the predictive ability of the nomogram in patients with Stage I LUAD in the TCGA-LUAD cohort and GEO datasets.

Indexed as

Adenocarcinoma of LungLung NeoplasmsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMachine LearningTumor MicroenvironmentGEOGGO (ground-glass opacity)LUADprognosisTCGA

Identifiers

PMID35693786
PMCPMC9178173
OpenAlexW4281568626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.